{
    "clinical_study": {
        "@rank": "38511", 
        "arm_group": [
            {
                "arm_group_label": "PCV-vaccinated infant, 3+1 schedule"
            }, 
            {
                "arm_group_label": "PCV-vaccinated infant, 2+1 schedule"
            }, 
            {
                "arm_group_label": "Control-vaccinated infant"
            }, 
            {
                "arm_group_label": "PCV-vaccinated child, catch-up schedule"
            }, 
            {
                "arm_group_label": "Control-vaccinated child, catch-up schedule"
            }
        ], 
        "biospec_descr": {
            "textblock": "Nasopharyngeal and oropharyngeal swabs"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the direct effects of the ten-valent pneumococcal\n      conjugate vaccine administered to infants on nasopharyngeal carriage at 3 to 5 years of age.\n\n      These children have been vaccinated in infancy in the cluster-randomized Finnish Invasive\n      pneumococcal Disease (FinIP) Trial (a separate protocol reported at ClinicalTrials.gov\n      Identifier:NCT00861380) during 2009 to 2011.\n\n      Also the indirect effect on nasopharyngeal carriage will be assessed on vaccinees' elder\n      non-vaccinated siblings aged 5 to 9 years."
        }, 
        "brief_title": "Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carriage of Streptococcus Pneumoniae", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "This study includes a cross-sectional sampling of nasopharyngeal and oropharyngeal swabs in\n      2013 from vaccinated and unvaccinated children."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria for FinIP-vaccinated children:\n\n          1. age 3 to 5 years\n\n          2. enrolled in the FinIP trial and has received at least one dose of study vaccine in\n             the infant vaccine schedule (3+1 or 2+1)\n\n          3. at least one parent with fluent Finnish\n\n          4. informed consent from one parent\n\n        Exclusion criteria for FinIP-vaccinated children\n\n          1. PCV vaccination administered, other than the randomized study vaccine\n\n          2. history of antimicrobial treatment within 4 weeks (the child can be enrolled later)\n\n        Inclusion criteria for unvaccinated siblings\n\n          1. age 5 to 9 years\n\n          2. younger sibling living in the same household having participated in the FinIP trial\n             (regardless of the vaccination schedule)\n\n          3. at least one parent with fluent Finnish\n\n          4. informed consent from one parent\n\n        Exclusion criteria for unvaccinated siblings\n\n          1. PCV vaccination administered\n\n          2. history of antimicrobial treatment within 4 weeks (the child can be enrolled later)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "9 Years", 
            "minimum_age": "3 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Children vaccinated in infancy in the cluster-randomized Finnish Invasive pneumococcal\n        Disease (FinIP) Trial (ClinicalTrials.gov Identifier:NCT00861380) during 2009 to 2011 and\n        their unvaccinated older siblings."
            }
        }, 
        "enrollment": {
            "#text": "3900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925222", 
            "org_study_id": "FinIP-carriage13THL"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 2, 2014", 
        "link": {
            "description": "Public webpage for the FinIP trial and the carriage study", 
            "url": "http://www.finip.fi"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampere", 
                    "country": "Finland", 
                    "zip": "33520"
                }, 
                "name": "National Institute for Health and Welfare"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_groups": "5", 
        "official_title": "Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme", 
        "other_outcome": {
            "measure": "Carriage due to any pneumococcal serotype included in the PCV vaccine in unvaccinated older siblings of the PCV10-vaccinated children", 
            "safety_issue": "No", 
            "time_frame": "one sampling at 5 to 9 years of age"
        }, 
        "overall_official": {
            "affiliation": "National Institute for Health and Welfare, Finland", 
            "last_name": "Arto A Palmu, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Finland: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Nasopharyngeal and oropharyngeal swabs taken once at 3 to 5 years of age", 
            "measure": "Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) in children vaccinated in infancy", 
            "safety_issue": "No", 
            "time_frame": "one sampling at 3 to 5 years of age"
        }, 
        "reference": {
            "PMID": "23158882", 
            "citation": "Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013 Jan 19;381(9862):214-22. doi: 10.1016/S0140-6736(12)61854-6. Epub 2012 Nov 16."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925222"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Institute for Health and Welfare, Finland", 
            "investigator_full_name": "Arto Palmu", 
            "investigator_title": "Research manager", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Carriage due to any pneumococcal serotype in children vaccinated in infancy", 
            "safety_issue": "No", 
            "time_frame": "one sampling at 3 to 5 years of age"
        }, 
        "source": "National Institute for Health and Welfare, Finland", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Arto Palmu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}